Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Adrenal Cortex Hormones
/ therapeutic use
Adult
Aged
Anti-Asthmatic Agents
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Asthma
/ drug therapy
Asthma, Aspirin-Induced
/ drug therapy
Disease Progression
Drug Therapy, Combination
Eosinophils
/ immunology
Female
Forced Expiratory Volume
Humans
Interleukin-5
/ antagonists & inhibitors
Leukocyte Count
Logistic Models
Male
Middle Aged
Multivariate Analysis
Retrospective Studies
Severity of Illness Index
Young Adult
Benralizumab
Eosinophilic asthma
Eosinophilic chronic rhinosinusitis
Global evaluation of treatment effectiveness
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
03 Aug 2020
03 Aug 2020
Historique:
received:
31
01
2020
accepted:
28
07
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
18
5
2021
Statut:
epublish
Résumé
Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in real life are available. The aim was to elucidate the efficacy of benralizumab by evaluating changes in clinical parameters after benralizumab treatment in patients with SEA. From July 2018 to December 2019, 24 Japanese patients with SEA received benralizumab at Jikei University Hospital. We retrospectively evaluated the patients' characteristics, parameters, numbers of exacerbations and maintenance OCS doses. Among the 24 patients, eleven patients had received mepolizumab treatment and were directly switched to benralizumab. The peripheral blood eosinophil and basophil counts significantly decreased after benralizumab treatment regardless of previous mepolizumab treatment. Pulmonary function, Asthma Control Test scores, the numbers of annual exacerbations and maintenance OCS doses in patients without previous mepolizumab treatment tended to improve without significant differences. Fourteen patients (58%) were responders according to the Global Evaluation of Treatment Effectiveness (GETE) score. The proportion of GETE responders among patients with aspirin-exacerbated respiratory disease (AERD) tended to be lower than that among patients without AERD (p = 0.085). After benralizumab treatment, the change in the forced expiratory volume in 1 s from baseline was 200 ml or greater in eight patients (33%), including three patients who were switched from mepolizumab. Benralizumab treatment improved and controlled asthma symptoms based on the GETE score.
Sections du résumé
BACKGROUND
BACKGROUND
Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in real life are available. The aim was to elucidate the efficacy of benralizumab by evaluating changes in clinical parameters after benralizumab treatment in patients with SEA.
METHODS
METHODS
From July 2018 to December 2019, 24 Japanese patients with SEA received benralizumab at Jikei University Hospital. We retrospectively evaluated the patients' characteristics, parameters, numbers of exacerbations and maintenance OCS doses.
RESULTS
RESULTS
Among the 24 patients, eleven patients had received mepolizumab treatment and were directly switched to benralizumab. The peripheral blood eosinophil and basophil counts significantly decreased after benralizumab treatment regardless of previous mepolizumab treatment. Pulmonary function, Asthma Control Test scores, the numbers of annual exacerbations and maintenance OCS doses in patients without previous mepolizumab treatment tended to improve without significant differences. Fourteen patients (58%) were responders according to the Global Evaluation of Treatment Effectiveness (GETE) score. The proportion of GETE responders among patients with aspirin-exacerbated respiratory disease (AERD) tended to be lower than that among patients without AERD (p = 0.085). After benralizumab treatment, the change in the forced expiratory volume in 1 s from baseline was 200 ml or greater in eight patients (33%), including three patients who were switched from mepolizumab.
CONCLUSION
CONCLUSIONS
Benralizumab treatment improved and controlled asthma symptoms based on the GETE score.
Identifiants
pubmed: 32746787
doi: 10.1186/s12890-020-01248-x
pii: 10.1186/s12890-020-01248-x
pmc: PMC7398222
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Asthmatic Agents
0
Antibodies, Monoclonal, Humanized
0
Interleukin-5
0
benralizumab
71492GE1FX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Références
NPJ Prim Care Respir Med. 2019 Apr 29;29(1):13
pubmed: 31036818
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1
pubmed: 19767070
Eur Respir J. 2018 Oct 18;52(4):
pubmed: 30139780
J Allergy Clin Immunol. 2019 Jan;143(1):190-200.e20
pubmed: 30205189
Allergol Int. 2018 Apr;67(2):266-272
pubmed: 29128192
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1061-1070.e3
pubmed: 28286156
Allergy. 2015 Jul;70(7):828-35
pubmed: 25855099
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
Lung. 2020 Feb;198(1):95-103
pubmed: 31894410
Allergol Int. 2017 Apr;66(2):163-189
pubmed: 28196638
J Allergy Clin Immunol. 2016 May;137(5):1585-1587.e4
pubmed: 26559322
N Engl J Med. 2017 Jun 22;376(25):2448-2458
pubmed: 28530840
Am J Respir Crit Care Med. 2015 Sep 15;192(6):682-94
pubmed: 26067893
Eur Respir J. 1999 Jul;14(1):23-7
pubmed: 10489824
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
Allergol Int. 2017 Jul;66(3):445-451
pubmed: 28110896
Respir Med. 2017 Oct;131:109-113
pubmed: 28947015
Allergol Int. 2019 Jul;68(3):289-295
pubmed: 31235242
Eur Respir J. 2020 May 21;55(5):
pubmed: 32139455
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S65-87
pubmed: 22386510
BMC Pulm Med. 2019 Oct 12;19(1):176
pubmed: 31606052
J Asthma. 2019 Sep 3;:1-6
pubmed: 31479312
Allergy Asthma Proc. 2018 Sep 4;39(5):345-349
pubmed: 30077185
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1045-1047
pubmed: 29501519
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Allergy Clin Immunol. 2015 Apr;135(4):896-902
pubmed: 25441637
Exp Mol Med. 2013 Mar 08;45:e14
pubmed: 23470716
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
Eur Respir J. 2018 Nov 29;52(5):
pubmed: 30309978
Lancet Respir Med. 2018 Jan;6(1):51-64
pubmed: 28919200
Allergy. 2016 Sep;71(9):1335-44
pubmed: 27087007